What It Does: Alnylam Pharmaceuticals develops RNA-based therapeutics targeting genetic diseases through RNAi (RNA interference) technology that silences disease-causing genes. The company generated $767 million in revenue for 2024, representing 104% year-over-year growth from $376 million in 2023, as multiple approved therapies ramped commercial adoption. Alnylam maintains a portfolio of five FDA-approved RNAi therapeutics for hereditary transthyretin amyloidosis (hATTR), primary biliary cholangitis, and rare genetic diseases. The company generated $432 million in product revenue in 2024, with gross margins of 79%, reflecting manufacturing scale and high pricing power for rare disease therapeutics. Pipeline products in clinical development target Huntington's disease, hemophilia, and other genetic disorders with potential peak sales exceeding $4 billion across approved and pipeline products. The RNAi therapeutic market remains underpenetrated globally, with only 15-20% of eligible patients currently treated, suggesting substantial runway for market expansion through diagnostic awareness and geographic expansion. Alnylam's technology platform enables rapid development of RNAi therapeutics across diverse disease targets, reducing development timelines and improving the probability of clinical success relative to traditional small molecule approaches.
How the Stock Looks: ALNY trades at 28x forward earnings, representing a reasonable multiple for high-growth biotech with limited earnings predictability and substantial clinical and commercial development risks. The stock gained 48% in 2024, outperforming broader biotech indices as investors increasingly recognize RNAi therapeutic potential and Alnylam's commercial execution capabilities. Goldman Sachs set a $225 price target (implying 55% upside), citing that peak sales potential across the approved portfolio could reach $2 billion annually by 2028, supporting substantial earnings power. Bernstein's $180 target assumes more conservative uptake rates and competitive threats from antisense oligonucleotide therapeutics but still implies 20%+ upside. Alnylam's approved revenue reached $432 million in 2024, with guidance suggesting continued 50%+ annual growth through 2026 as patient uptake accelerates and geographic expansion proceeds. Management's focus on earlier-stage development and expanded indications for approved therapies creates multiple value drivers. The company maintains a strong balance sheet with $1.5 billion in cash, enabling funding of late-stage pipeline development without near-term capital raises.
What Analysts Are Saying: TipRanks consensus shows 12 Buy and 4 Hold ratings with $205 average target, indicating moderate support with some skepticism. MarketBeat data reveals mixed sentiment reflecting both RNAi therapeutic optimism and clinical/competitive risks as the platform technology's broader clinical applicability remains unproven. Wedbush initiated coverage at Outperform, citing that RNAi therapeutics represent a significant untapped market opportunity and that Alnylam's manufacturing expertise and approved portfolio provide competitive advantages. The bull case assumes each approved indication ultimately penetrates 40-50% of eligible patient populations, generating cumulative annual revenues exceeding $3 billion. JPMorgan maintains Overweight, highlighting that recent FDA approvals for ATTR and PBC indications validate RNAi therapeutic efficacy and that Alnylam's pipeline breadth reduces clinical execution risk. Bears worry that patient adoption remains slower than optimistic scenarios and that manufacturing supply chain challenges could constrain revenue growth. The key catalysts for near-term performance include clinical trial readouts for Huntington's disease and hemophilia programs, which could substantially expand addressable market opportunity.